• Something wrong with this record ?

Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial

J. Malouf-Sierra, U. Tarantino, PA. García-Hernández, C. Corradini, S. Overgaard, JJ. Stepan, L. Borris, E. Lespessailles, F. Frihagen, K. Papavasiliou, H. Petto, P. Aspenberg, JR. Caeiro, F. Marin,

. 2017 ; 32 (5) : 1040-1051. [pub] 20170126

Language English Country United States

Document type Journal Article, Multicenter Study, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc18010881

We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture. Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug. Primary endpoint was change from baseline in lumbar spine (LS) BMD at 78 weeks. Secondary and exploratory endpoints were change in BMD at the proximal femur, function, hip pain (Charnley score and 100 mm Visual Analog Scale [VAS]), quality of life (Short Form-36), radiology outcomes, and safety. Data were analyzed with mixed models for repeated measures (MMRM) and logistic regression. Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females). Mean baseline LS, femoral neck (FN), and total hip (TH) T-scores were -2.16, -2.63, and -2.51, respectively. At 78 weeks, BMD increased significantly more with teriparatide compared to risedronate at the LS (+11.08% versus +6.45%; p < 0.001) and FN (+1.96% versus -1.19%; p = 0.003), with no significant between-group difference in TH BMD. Timed up-and-go (TUG) test was significantly faster with teriparatide at 6, 12, 18, and 26 weeks (differences: -3.2 to -5.9 s; p = 0.045 for overall difference). Hip pain during TUG test by 100 mm VAS was significantly lower with teriparatide at 18 weeks (adjusted difference: -11.3 mm, p = 0.033; -10.0 and -9.3 mm at 12 and 26 weeks, respectively; p = 0.079 for overall difference). Other secondary and exploratory outcomes were not different. Teriparatide group showed two new hip fractures versus seven with risedronate (p = 0.171) and more frequent hypercalcemia and hyperuricemia. In conclusion, 78-week treatment with teriparatide showed significantly greater increases in LS and FN BMD, less pain, and a faster TUG test versus risedronate. © 2016 American Society for Bone and Mineral Research.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010881
003      
CZ-PrNML
005      
20180418134214.0
007      
ta
008      
180404s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jbmr.3067 $2 doi
035    __
$a (PubMed)28019683
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Malouf-Sierra, Jorge $u Internal Medicine, Hospital San Pablo, Barcelona, Spain.
245    10
$a Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial / $c J. Malouf-Sierra, U. Tarantino, PA. García-Hernández, C. Corradini, S. Overgaard, JJ. Stepan, L. Borris, E. Lespessailles, F. Frihagen, K. Papavasiliou, H. Petto, P. Aspenberg, JR. Caeiro, F. Marin,
520    9_
$a We present final results of a study comparing teriparatide 20 μg every day (QD) with risedronate 35 mg once per week (QW) started within 2 weeks after surgery for a pertrochanteric hip fracture. Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug. Primary endpoint was change from baseline in lumbar spine (LS) BMD at 78 weeks. Secondary and exploratory endpoints were change in BMD at the proximal femur, function, hip pain (Charnley score and 100 mm Visual Analog Scale [VAS]), quality of life (Short Form-36), radiology outcomes, and safety. Data were analyzed with mixed models for repeated measures (MMRM) and logistic regression. Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efficacy analyses (mean ± SD age: 77 ± 7.7 years, 77% females). Mean baseline LS, femoral neck (FN), and total hip (TH) T-scores were -2.16, -2.63, and -2.51, respectively. At 78 weeks, BMD increased significantly more with teriparatide compared to risedronate at the LS (+11.08% versus +6.45%; p < 0.001) and FN (+1.96% versus -1.19%; p = 0.003), with no significant between-group difference in TH BMD. Timed up-and-go (TUG) test was significantly faster with teriparatide at 6, 12, 18, and 26 weeks (differences: -3.2 to -5.9 s; p = 0.045 for overall difference). Hip pain during TUG test by 100 mm VAS was significantly lower with teriparatide at 18 weeks (adjusted difference: -11.3 mm, p = 0.033; -10.0 and -9.3 mm at 12 and 26 weeks, respectively; p = 0.079 for overall difference). Other secondary and exploratory outcomes were not different. Teriparatide group showed two new hip fractures versus seven with risedronate (p = 0.171) and more frequent hypercalcemia and hyperuricemia. In conclusion, 78-week treatment with teriparatide showed significantly greater increases in LS and FN BMD, less pain, and a faster TUG test versus risedronate. © 2016 American Society for Bone and Mineral Research.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a fraktury kyčle $x krev $x farmakoterapie $x patologie $7 D006620
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    _2
$a kyselina risedronová $x aplikace a dávkování $x škodlivé účinky $7 D000068296
650    _2
$a teriparatid $x aplikace a dávkování $x škodlivé účinky $7 D019379
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Tarantino, Umberto $u Orthopaedic Surgery, University Tor Vergata, Rome, Italy.
700    1_
$a García-Hernández, Pedro A $u Osteoporosis Center, University Hospital, Monterrey, Mexico.
700    1_
$a Corradini, Costantino $u Department of Biomedical Surgical and Dental Sciences, University of Milan, c/o 1st University Division of Orthopaedy and Traumatology, ASST Gaetano Pini, Milan, Italy.
700    1_
$a Overgaard, Søren $u Department of Orthopaedic Surgery and Traumatology, Odense University Hospital Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
700    1_
$a Stepan, Jan J $u Institute of Rheumatology and Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Borris, Lars $u Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark.
700    1_
$a Lespessailles, Eric $u Institut de prévention et de recherche sur l'ostéoporose (IPROS), Department of Rheumatology, Centre Hospitalier Régional (CHR) d'Orléans, Orléans, France. Imagerie Multimodale Multiéchelle et Modélisation du Tissu Osseux (I3MTO), EA 4708, Orléans University, Orléans, France.
700    1_
$a Frihagen, Frede $u Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.
700    1_
$a Papavasiliou, Kyriakos $u 3rd Orthopaedic Department, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.
700    1_
$a Petto, Helmut $u Eli Lilly, Vienna, Austria.
700    1_
$a Aspenberg, Per $u Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
700    1_
$a Caeiro, José Ramón $u Department of Orthopaedic Surgery and Traumatology, Santiago de Compostela University Hospital, Health Research Institute, University of Santiago de Compostela, Santiago de Compostela, Spain.
700    1_
$a Marin, Fernando $u Eli Lilly Research Centre Ltd, Erl Wood Manor, Surrey, UK.
773    0_
$w MED00002559 $t Journal of bone and mineral research the official journal of the American Society for Bone and Mineral Research $x 1523-4681 $g Roč. 32, č. 5 (2017), s. 1040-1051
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28019683 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180418134314 $b ABA008
999    __
$a ok $b bmc $g 1288366 $s 1007693
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 32 $c 5 $d 1040-1051 $e 20170126 $i 1523-4681 $m Journal of bone and mineral research $n J Bone Miner Res $x MED00002559
LZP    __
$a Pubmed-20180404
Back

Find record

Citation metrics

Archiving options